title: Increase in serum magnesium level in haemodialysis patients receiving sevelamer hydrochloride.
abstract: BACKGROUND
  Clinical studies have shown that sevelamer hydrochloride improves lipid profiles and attenuates the progression of the cardiovascular calcifications in haemodialysis patients. It is known that both of these properties are associated with increased magnesium levels. The effect of sevelamer on serum magnesium level is not well documented. The aim of this study was to determine the effects of sevelamer treatment on serum magnesium in haemodialysis patients and to assess the association of magnesium levels with lipid profiles and intact parathyroid hormone (iPTH).
  
  
  METHODS
  Phosphate binders were discontinued during a two week washout period. Forty-seven patients, whose serum phosphate was greater than 6.0 mg/dl at the end of washout, received sevelamer hydrochloride for eight weeks. The patients were then washed off sevelamer for another two weeks.
  
  
  RESULTS
  Mean serum phosphorus concentration declined from 7.5 +/- 1.3 to 6.4 +/- 1.2 mg/dl (P < 0.001), mean serum magnesium levels increased from 2.75 +/- 0.35 to 2.90 +/- 0.41 mg/dl (P < 0.001) and median serum iPTH levels decreased from 297 to 213 pg/ml (P=0.001) during the eight weeks of sevelamer treatment. After the two week post-treatment washout phosphorus levels increased to 7.3 +/- 1.3 mg/dl (P < 0.001), magnesium levels were reduced to 2.77 +/- 0.39 mg/dl (P < 0.001) and iPTH levels increased to 240 pg/ml (P=0.012). No change was observed in serum calcium levels during the sevelamer treatment period and the subsequent washout period. The mean decline in total and low density lipoprotein (LDL) cholesterol during sevelamer treatment was 16.3 and 28.3 (P < 0.001), respectively. The mean increase in high density lipoprotein (HDL) cholesterol and in apolipoprotein A1 was 2.9 +/- 5.8 mg/dl (P=0.004) and 6.8 +/- 11.1 mg/dl (P=0.001), respectively. Multivariate analysis showed that the rise in serum magnesium concentration significantly correlated with reductions in iPTH levels (r=-0.40, P=0.016), but did not have any significant correlation with the changes in lipid profiles.
  
  
  CONCLUSIONS
  Our findings indicate that patients on haemodialysis receiving sevelamer have a significant increase in serum magnesium concentrations. This increase in serum magnesium is associated with reduction in iPTH levels. The changes in lipid profiles of these patients however are not related to changes in serum magnesium levels.
authors.affiliation: Department of Nephrology, Papageorgiou General Hospital, Thessaloniki, Greece. mitsopouloss@yahoo.com
authors.forename: Efstathios
authors.initials: E
authors.lastname: Mitsopoulos
authors.forename: Ioannis
authors.initials: I
authors.lastname: Griveas
authors.forename: Stavros
authors.initials: S
authors.lastname: Zanos
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Anagnostopoulos
authors.forename: Anastasia
authors.initials: A
authors.lastname: Giannakou
authors.forename: Aikaterini
authors.initials: A
authors.lastname: Pavlitou
authors.forename: Georgios
authors.initials: G
authors.lastname: Sakellariou
mesh_terms: D005260:Female; D006801:Humans; D008274:Magnesium / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011073:Polyamines / Q000494:pharmacology*; D006435:Renal Dialysis; D000069603:Sevelamer
chemical_list: D011073:Polyamines; D000069603:Sevelamer; D008274:Magnesium